Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.60EUR
22 Jul 2016
Change (% chg)

-- (--)
Prev Close
€76.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,787,523
52-wk High
€101.10
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.76
Market Cap(Mil.): €98,592.30
Shares Outstanding(Mil.): 1,287.11
Dividend: 2.93
Yield (%): 3.83

Financials

  SASY.PA Industry Sector
P/E (TTM): 22.68 36.47 37.34
EPS (TTM): 3.38 -- --
ROI: -- 14.88 14.14
ROE: -- 15.96 15.35

BRIEF-Sanofi Enzyme says Ontario adds LEMTRADA to exceptional access program for eligible patients

* Ontario adds Lemtrada (Alemtuzumab) to exceptional access program for eligible patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

21 Jul 2016

Sanofi offers EU concessions over Boehringer consumer healthcare deal

BRUSSELS - French drugmaker Sanofi has sought to address EU antitrust concerns over its proposed takeover of German peer Boehringer Ingelheim's consumer health unit by offering concessions.

18 Jul 2016

Sanofi offers EU concessions over Boehringer consumer healthcare deal

BRUSSELS, July 18 - French drugmaker Sanofi has sought to address EU antitrust concerns over its proposed takeover of German peer Boehringer Ingelheim's consumer health unit by offering concessions.

18 Jul 2016

Drugmaker Boehringer offers EU concessions for Sanofi asset swap

BRUSSELS - German drugmaker Boehringer Ingelheim has offered concessions in an attempt to win EU antitrust approval for its $20 billion asset swap with France's Sanofi , which would make it the second-largest company in the global animal health market.

08 Jul 2016

Drugmaker Boehringer offers EU concessions for Sanofi asset swap

BRUSSELS, July 8 - German drugmaker Boehringer Ingelheim has offered concessions in an attempt to win EU antitrust approval for its $20 billion asset swap with France's Sanofi, which would make it the second-largest company in the global animal health market.

08 Jul 2016

Medivation agrees to open its books to Sanofi

U.S. cancer drug company Medivation Inc said on Tuesday it had agreed to provide confidential information to French pharmaceutical company Sanofi SA as part of exploring a sale that would be open to other bidders. | Video

06 Jul 2016

Deals of the day-Mergers and acquisitions

July 6 The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday:

06 Jul 2016

BRIEF-Sanofi Genzyme begins pivotal phase 2/3 trial

* Sanofi Genzyme begins pivotal phase 2/3 trial of olipudase alfa for adult patients with acid sphingomyelinase deficiency Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

06 Jul 2016

France's Sanofi partners U.S. Army to speed up Zika vaccine

PARIS/LONDON French drugmaker Sanofi said on Wednesday it had struck a research and development deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus.

06 Jul 2016

UPDATE 2-France's Sanofi partners U.S. Army to speed up Zika vaccine

* French firm only big drugmaker actively working on Zika (Adds further details on vaccine development)

06 Jul 2016

Earnings vs. Estimates